Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers R > Headlines for Royalty Pharma > News item |
S&P gives BBB- to RPI Finance loan
S&P said it assigned a BBB- issue-level rating to RPI Finance Trust's (doing business as Royalty Pharma) new term loan A.
The transaction does not affect leverage.
The company will use the proceeds to repay its existing term loan A.
S&P said the BBB- corporate credit rating on RPI reflects its position as the largest and leading pharmaceutical royalty acquisition company, with a proven track record and a relatively broad portfolio by product and by marketer.
The agency anticipates the company will continue to make acquisitions of approximately $1 billion annually, but it expects the company will operate with operating cash flow to debt, including milestone payment receipts and distributions to minority interest, of between 15% and 25%.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.